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Introduction
Chronic kidney disease (CKD) is a public health problem
and its prevalence is growing all over the world, and the
same is the case in Iran.1 Anaemia is a major complication
in CKD patients.2 The aetiology of anaemia in CKD is
multifactorial.3 The relative erythropoietin deficiency,
shortened erythrocyte survival and the erythropoiesis
inhibitory effects of accumulating uraemic toxins
contribute to the anaemia in CKD.3 Importantly, CKD
patients have several abnormalities in systemic
homeostasis of iron, an essential component in the
production of red blood cells (RBCs).3 Poor absorption of
dietary iron in CKD patients and failure in the use of iron
stores may cause anaemia.2,3 According to recent
researches, hepcidin is one of the main causes of
disturbances in iron metabolism in CKD and anaemia.4,5 It
regulates systemic iron balance by decreasing both
intestinal iron absorption and iron release from
enterocytes, hepatocytes and macrophages leading to
hypoferremia and limits iron availability for
erythropoiesis.4 Hepcidin concentration increases in CKD
due to inflammation and renal clearance reduction.5
Resistance to erythropoietin in CKD can be caused by high
concentrations of hepcidin and iron limitation.6 Despite
the central role of hepcidin in the metabolism of iron,
limited data is available to link hepcidin and anaemia in
CKD stage 4 and there are controversial issues in this case.7
The current study was planned to assess possible
relationships of serum hepcidin levels with haemoglobin
levels, inflammation and iron statuses in stage 4 CKD
patients.
Materials and Methods
The cross-sectional study was conducted at the
Department of Biochemistry, Tabriz University of Medical
Sciences (TUMS), Iran, from March 2011 through October
2012, and comprised CKD stage 4 patients in Ardabil
hospitals after approval from the institutional ethics
committee. The sample size was based on the
inclusion/exclusion criteria indicated in earlier studies.8-10
Adult patients (>18 years) with anaemia who had CKD
stage 4 with glomerular filtration rate (GFR) 15-29
ml/min/1.73 m2 were included in the study. Anaemia was
defined as haemoglobin levels of less than 13g/dl for men
and postmenopausal women, and less than 12g/dl for
premenopausal women.11 Subjects with transfusion
within the preceding 6 months, myocardial infarction (MI)
history within the preceding 3 months, surgical history
within the preceding 3 months, malignancy, diastolic
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blood pressure (DBP) greater than 100mm/hg,
uncontrolled diabetes, severe hyperparathyroidism
(parathyroid hormone [PTH]>800pg/ml) and consumers
of drugs such as angiotensin receptor blockers and
angiotensin-converting enzyme inhibitors were excluded.
Following overnight fast, blood samples were obtained
from the patients. GFR was calculated by the Cockcroft-
Gault formula.12 Blood haemoglobin (Hb) and
haematocrit (Ht) levels were measured by blood cell
counter (Sysmex KX-21N, Japane). Separated serum and
whole blood were kept frozen at -80°C until analysis. Sera
samples were analysed using an auto-analyser (BT3000,
Italy) and manufacturer's reagent kits for serum
biomarkers such as high sensitivity C-reactive protein (hs-
CRP), total iron binding capacity (TIBC), iron, calcium,
phosphorus, magnesium, urea, creatinine, albumin and
total protein. Serum hepcidin and ferritin levels were
assayed by standard enzyme linked immunosorbent
assay (ELISA) kits (Cusabio and DiaPlus, China, USA,
respectively). Serum concentrations of interleukin 6 (IL-6)
were measured using human ELISA kits according to the
manufacturer's instructions (Bender Med Systems, Vienna,
Austria). These biochemical factors were assayed using
fully automated ELISA analyser (TKA Teknolabo Bizet,
Italy). Serum PTH levels were measured through a
chemiluminescent method (Liaison, USA).
The collected data was analysed using statistical methods
such as Pearson's Correlation Coefficient and Scatter plot. P
value less than 0.05 was considered statistically significant.
Results
There were 40 patients among whom 15(37.5%) were
males and 25(62.5%) were females with an overall mean
age of 55.68±14.4 years. There was a significant inverse
relationship between serum hepcidin concentrations and
Hb levels (p<0.05). No significant relationship between
serum iron and serum hepcidin was found (p>0.05). An
inverse significant correlation between serum levels of
hepcidin and TIBC was observed (p<0.001). Hepcidin had
an inverse significant relationship with albumin and PTH
levels (p<0.05). There was a positive significant
relationship of hepcidin serum levels with IL-6 and ferritin
serum levels (p<0.05 each). There was a significant
positive correlation between Hb and ferritin levels
(p<0.05 each). There was no significant relationship of
hepcidin with serum hs-CRP and GFR.
Discussion
Anaemia is one of the major complications of CKD and its
pathogenesis has not been well understood.13
Inflammation is an important factor associated with
erythropoietin resistance and the occurrence of anaemia in
patients with CKD.14 It has been shown that hepcidin
expression is part of an inflammatory reaction and it may be
involved in the pathogenesis of inflammation-associated
anaemia.15 In our study, serum hepcidin concentrations
were negatively associated with Hb levels and it had strong
positive correlation with IL-6 levels. Our results are
inconsistent with the results of some studies in CKD
patients. Studies in non-dialysis CKD patients could not find
association between serum hepcidin concentration and Hb
level.5,16 A study comprising renal insufficiency patients also
could not find any relation between Hb levels and serum
prohepcidin concentrations.17 Our results are consistent
with the results of other studies in dialysis patients and in
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Table-1: Clinical characteristics.
Parameter Mean ± SE Parameter Mean ± SE Parameter Mean ± SE
(Mean ± SD) (Mean ± SD) (Mean ± SD)
Hepcidin (ng/ml) 258.86 ± 21.94 hs-CRP (mg/l) 10.54 ± 1.89 Creatinin (mg/dl) 3.66 ± 0.15
(258.86 ± 138.76) (12.82 ± 13.74) (3.66 ± 0.96)
IL-6 (pg/ml)** 0.59 ±3.39 TIBC (µg/dl)* 295.05 ± 8.18 Phosphorus (mg/dl) 4.36 ± 0.12
(5.57 ± 9.25) (295.05 ± 51.79) (4.36 ± 0.77)
Haemoglobin (g/dl)* 10.01 ± 0.24 Hematocrit (%) 31.15 ± 0.69 Weight (kg) 72.4 ± 1.73
(10.01 ± 1.56) (31.15 ± 4.39) (72.40 ± 10.95)
GFR (ml/min/1.73 m2) 21.51 ± 0.74 Urea (mg/dl) 126.38 ± 7.12 PTH (pg/ml)* 111.93 ± 13.35
(21.51 ± 4.71) (126.37 ± 45.02) (152.11 ± 146.10)
Ferritin (µg/l)** 163.83 ± 24.69 Albumin (g/dl)* 4.21 ± 0.11 Magnesium (mg/dl) 2.01 ± 0.04
(241.06 ± 276.36) (4.21 ± 0.74) (2.01 ± 0.29)
Iron (µg/dl)** 63.5 ± 4.64 Total protein(g/dl) 8.11 ± 0.17 Calcium (mg/dl) 9.03 ± 0.11
(63.50 ± 29.39) (8.11 ± 1.07) (9.03 ± 0.75)
TIBC= Total Iron Binding Capacity, IL-6= interleukin-6, PTH= parathyroid hormone, GFR= Glomerular filtration rate.
*An inverse significant relationship with hepcidin in Pearson Correlation (p<0.05).
**A positive significant relationship with hepcidin in Pearson Correlation (p<0.05).
patients with both heart and kidney failure.15,18 These
conflicting results may be attributable to differences in the
iron status of the populations studied, differences in
inflammatory state or sample size. There are several reasons
why hepcidin may be negatively associated with Hb in stage
4 CKD patients with sufficient iron stores.19 For one, hepcidin
as central modulator of iron controls the expression of
ferroportin (the major transporter of iron) on intestinal cells
and macrophages and limits iron availability for
erythropoiesis.20 High-ferritin levels in serum normally
indicate iron overload, but this does not necessarily mean
sufficient bone marrow iron stores.21 Another reason is that
hepcidin is induced by inflammation,2 and patients with
CKD have a chronic inflammatory state.3 The effects of
inflammation on the synthesis of hepcidin are well
understood and are mediated at least in part by IL-6. The
third reason is that besides inducing iron-restricted
erythropoiesis, hepcidin directs inhibitory effects on
erythropoiesis and affects erythroid precursor proliferation
and survival.22 Lastly, diminished renal clearance in CKD
patients also elevates hepcidin serum concentration and
exacerbates its effects.4 Thus, hepcidin excess has emerged
as one of the key pathogenic features of inflammation-
associated anaemia and reduction of Hb levels in stage 4
CKD patients.
We observed a significant positive correlation between
hepcidin and ferritin as widely used marker of iron
status.23 In agreement with our study, it has been shown
that IL-6 and other inflammatory cytokines may change in
concentrations of not only serum hepcidin, but also iron
status markers.24 A study in patients with inflammation-
associated anaemia reported that hepcidin level
correlates well with the serum ferritin concentration.25 A
study in haemodialysis patients described that hepcidin
level correlates with TIBC and ferritin concentrations.26
One study in patients with chronic liver disease showed
that hepcidin level correlated with ferritin level.27 In line
with these and other findings,26,28 our results suggest that
synthesis of hepcidin is also enhanced by an increased
body iron store. A significant positive correlation between
hepcidin and ferritin indicates the association between
hepcidin and iron stores in stage 4 CKD patients. Our
study showed that the raised hepcidin in stage 4 CKD
patients may be due to elevated ferritin levels and
elevated IL-6 due to inflammation status.
The low number of patients with stage 4 CKD and removal
of subjects based on the inclusion/exclusion criteria were
limitations of our study.
Conclusions
Hepcidin had negative correlation with Hb level in stage 4
CKD patients with adequate iron stores, which could be
effective in the development of anaemia in these patients.
Further studies are needed to examine longitudinal
changes in hepcidin, Hb, iron status indicators and
inflammatory cytokines such as IL-6 in stage 4 CKD
patients.
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